SCYX Q1 2023 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$38M

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1M+64.5% YoY

Gross Profit

$993,00087.9% margin

Operating Income

-$11M-945.3% margin

Net Income

-$34M-2997.9% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

-25.9%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$707,000

Balance Sheet

Total Assets

$70M

Total Liabilities

$100M

Stockholders' Equity

-$30M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$687,000	+64.5%
Gross Profit	$993,000	$588,000	+68.9%
Operating Income	-$11M	-$20M	+45.9%
Net Income	-$34M	-$5M	-521.5%